To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Ridgemont inks fourth deal since spin-out
The firm has purchased a majority stake in Gallus BioPharmaceuticals, its fourth acquisition since spinning out of Bank of America last August.
